Dr Xueyan Chen, Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders and National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, E-mail address:
J Prev Alzheimers Dis. 2024;11(6):1775-1788. doi: 10.14283/jpad.2024.119.
The functions of regulated cell death (RCD) are closely related to Alzheimer's disease (AD). However, very few studies have systematically investigated the diagnosis and immunologic role of RCD-related genes in AD patients.
8 multicenter AD cohorts were included in this study, and then were merged into a meta cohort. Then, an unsupervised clustering analysis was carried out to detect unique subtypes of AD based on RCD-related genes. Subsequently, differently expressed genes (DEGs) and weighted correlation network analysis (WGCNA) between subtypes were identified. Finally, to establish an optimal risk model, an RCD.score was constructed by using computational algorithm (10 machine-learning algorithms, 113 combinations).
We identified two distinct subtypes based on RCD-related genes, each exhibiting distinct hallmark pathway activity and immunologic landscape. Specifically, cluster.A patients had a higher immune infiltration, a higher immune modulators and poor AD progression. Utilizing the shared DEGs and WGCNA of these subtypes, we constructed an RCD.score that demonstrated excellent predictive ability in AD across multiple datasets. Furthermore, RCD.score was identified to exhibit the strongest association with poor AD progression. Mechanistically, we observed activation of signaling pathways and effective immune infiltration and immune modulators in the high RCD.score group, thus leading to a poor AD progression. Additionally, Mendelian randomization screening revealed four genes (CXCL1, ENTPD2, METTL7A, and SERPINB6) as feature genes for AD.
The RCD model is a valuable tool in categorizing AD patients. This model can be of great assistance to clinicians in determining the most suitable personalized treatment plan for each individual AD patient.
调控细胞死亡(RCD)的功能与阿尔茨海默病(AD)密切相关。然而,很少有研究系统地研究 RCD 相关基因在 AD 患者中的诊断和免疫作用。
本研究纳入了 8 个多中心 AD 队列,然后将其合并为一个荟萃队列。然后,基于 RCD 相关基因进行无监督聚类分析,以检测 AD 的独特亚型。随后,鉴定亚型间差异表达基因(DEGs)和加权相关网络分析(WGCNA)。最后,通过计算算法(10 种机器学习算法,113 种组合)构建 RCD.score,以建立最佳风险模型。
我们基于 RCD 相关基因确定了两种不同的亚型,每种亚型都表现出不同的标志性途径活性和免疫景观。具体而言,cluster.A 患者具有更高的免疫浸润、更高的免疫调节剂和较差的 AD 进展。利用这些亚型的共享 DEGs 和 WGCNA,我们构建了一个 RCD.score,该评分在多个数据集的 AD 中表现出出色的预测能力。此外,RCD.score 被确定与较差的 AD 进展具有最强的关联。从机制上看,我们观察到高 RCD.score 组中信号通路的激活以及有效的免疫浸润和免疫调节剂,从而导致 AD 进展较差。此外,孟德尔随机化筛选揭示了四个基因(CXCL1、ENTPD2、METTL7A 和 SERPINB6)作为 AD 的特征基因。
RCD 模型是一种有价值的 AD 患者分类工具。该模型可以为临床医生提供帮助,为每个 AD 患者确定最合适的个性化治疗方案。